Please try another search
Baxalta Incorporated, a biopharmaceutical company, develops, manufactures, and markets products for the treatment of hemophilia, immunology, and oncology. It provides products for the treatment of bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiencies, burns, shock, and other chronic and acute medical conditions, as well as acute lymphoblastic leukemia. The company offers ADVATE, a recombinant factor VIII therapy for the treatment of children and adults with hemophilia A; FEIBA, an inhibitor management therapy; and GAMMAGARD LIQUID, a liquid formulation of the antibody-replacement therapy for the treatment of primary immunodeficiency. Baxalta Incorporated was incorporated in 2014 and is based in Bannockburn, Illinois with additional offices in Zug, Switzerland; Westlake Village and Newbury Park, California; Lexington, Massachusetts; and Chicago, Illinois. Baxalta Incorporated operates as a subsidiary of Dyax Corp.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review